Correction of carbohydrate metabolism by genetically engineered insulin in rats with diabetic kidney disease

The aim of the study was to correct carbohydrate metabolism with genetically engineered insulin VINSUVET Glargine ANIMALPEN in rats with diabetic kidney disease. The work showed that in Wistar rats (n=96) with experimental diabetic kidney disease against the background of hypoinsulinemia and uncompensated hyperglycemia, glucose transport in the proximal tubules of the kidneys is impaired, manifested by glucosuria, the intensity of glycosylation of blood plasma proteins increases, and lactate utilization and metabolism are impaired. The course use of genetically engineered insulin VINSUVET Glargine ANIMALPEN in rats with diabetic kidney damage, at a dose of 0,5 IU/kg of body weight, for 80 days, has a positive effect on carbohydrate metabolism, which is characterized by a reliable increase in endogenous functionality in relation to glucose and lactate, a decrease in the content of fructosamine in the blood, ketone bodies in the blood and urine.